MABVAX THERAPEUTICS HLDGS INC
MBVX
MBVX was delisted on the 10th of July, 2018.
11 hedge funds and large institutions have $1.72M invested in MABVAX THERAPEUTICS HLDGS INC in 2018 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less capital invested
Capital invested by funds: $2.29M → $1.72M (-$569K)
27% less funds holding
Funds holding: 15 → 11 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$274K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$26.4K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.48K |
| 4 |
FANJ
Financial Architects (New Jersey)
Marlton,
New Jersey
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$84.8K |
| 2 |
VF
Virtu Financial
New York
|
-$69K |
| 3 |
BW
Bison Wealth
Atlanta,
Georgia
|
-$11K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.07K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $1.48M | -$84.8K | -39,225 | -4% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $191K | +$274K | +126,592 | New |
|
|
3
Commonwealth Equity Services
Waltham,
Massachusetts
| $18K | +$26.4K | +12,203 | New |
|
|
BCM
4
Biomark Capital Management
Greenwich,
Connecticut
| $13K | – | – | – |
|
5
Bank of America
Charlotte,
North Carolina
| $10K | -$2 | -1 | -0% |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | +$6.48K | +2,999 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $2K | -$9.07K | -4,197 | -72% |
|
|
BCI
8
Brinker Capital Investments
Berwyn,
Pennsylvania
| $1K | – | – | – |
|
|
VF
9
Virtu Financial
New York
| – | -$69K | -33,038 | Closed |
|
|
BW
10
Bison Wealth
Atlanta,
Georgia
| – | -$11K | -5,000 | Closed |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$9K | -4,133 | Closed |
|
|
BJL
12
Brighton Jones LLC
Seattle,
Washington
| – | -$7K | -3,333 | Closed |
|
|
DRD
13
Dennis R. Delaney
| – | -$7K | -3,333 | Closed |
|
|
FANJ
14
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | +$4 | +2 | New |
|
MBVX Hedge Fund Activity: Q1 2018 in Review
11 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in MABVAX THERAPEUTICS HLDGS INC (MBVX) for Q1 2018, worth a combined $1.72M — down 25% from $2.29M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MBVX and 4 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 0 added.
The largest buyer was Vanguard Group, opening a new position worth an estimated $274K. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $84.8K.
- 11 institutional investors held MABVAX THERAPEUTICS HLDGS INC (MBVX) as of Q1 2018, down from 15 in Q4 2017.
- Funds reported $1.72M of MABVAX THERAPEUTICS HLDGS INC stock for Q1 2018, down 25% quarter-over-quarter.
- 4 funds opened new MABVAX THERAPEUTICS HLDGS INC positions in Q1 2018 and 8 closed out, a net change of -4 holders.
- The largest MABVAX THERAPEUTICS HLDGS INC buyer in Q1 2018 was Vanguard Group, an estimated $274K added.
- The largest MABVAX THERAPEUTICS HLDGS INC seller in Q1 2018 was Cambridge Investment Research Advisors, an estimated $84.8K sold.
Based on aggregated 13F filings for Q1 2018.